
    
      This is a Phase 2, randomized, double-blind, placebo controlled study to assess the efficacy,
      tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week
      screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at
      Week 22. The total participation period is approximately 24 weeks.
    
  